Wegovy, Novo Nordisk's weight-loss drug, demonstrates improved heart failure symptom outcomes in diabetic patients, according to a New England Journal of Medicine study.

Novo Nordisk's weight-loss medication Wegovy shows promising results in treating heart failure symptoms among patients with diabetes, according to a study published in the New England Journal of Medicine. Wegovy patients reported less fatigue, leg swelling, shortness of breath, and improved walking ability compared to those on a placebo. The study supports the use of Wegovy in treating health conditions linked to obesity.